Published online Feb 27, 2021. doi: 10.4240/wjgs.v13.i2.141
Peer-review started: November 12, 2020
First decision: December 12, 2020
Revised: December 24, 2020
Accepted: January 14, 2021
Article in press: January 14, 2021
Published online: February 27, 2021
Processing time: 83 Days and 14 Hours
Gastrointestinal (GI) related diseases account for over $100 billion in healthcare expenditures in the United States.
Currently, few population-based studies are evaluating key hospital metrics such as thirty-day readmission rates, mortality and predictors of thirty-day readmissions for the most common GI diseases as a whole. Obtaining this information can provide further insights for clinicians and key stakeholders in recognizing the impact of these diseases and identifying opportunities for improved healthcare delivery.
We aimed to find the most common GI-related illnesses and calculate the total index admissions, thirty-day readmission rates, mean length of stay, mean hospitalization costs, and the mortality rates for each of these diseases. We also sought to assess predictors of thirty-day readmissions for these conditions.
The Nationwide Inpatient Sample (2012) identified the 13 most common GI and Liver disease hospitalizations, which included GI hemorrhage, cholelithiasis with cholecystitis, acute pancreatitis, and Clostridium difficile (C. difficile) infection. The 2013 Nationwide Readmission Database was then queried with each disease to obtain hospital outcomes and readmission data. Multivariable logistic regression analyses for each disease group identified predictors for thirty-day readmission.
The thirteen GI diseases accounted for 2.4 million index hospitalizations and $25 billion in healthcare-associated costs. Chronic conditions such as those involving the liver, functional/motility disorders and inflammatory bowel disease were associated with high readmission rates, mortality rates and hospitalization costs. However, potentially preventable and non-chronic GI ailments such as GI hemorrhage, acute pancreatitis and C. difficile infection were also linked with considerable readmission rates, mortality rates and hospitalization costs. Patient variables such as type of insurance, presence of ≥ 3 Elixhauser comorbidities, and length of stay > 3 d were predictors of thirty-day readmission for all the thirteen GI diseases.
GI-related diseases contribute to substantial inpatient morbidity, mortality and healthcare resource utilization. Our study highlighted the sizeable portion of readmissions, mortality rates and hospitalization costs attributed to potentially preventable and non-chronic GI diseases such as C. difficile infection, gastrointestinal bleeding, and acute pancreatitis.
Our study identifies a need for improved healthcare quality and a stronger emphasis on preventative medicine to decrease the overall GI burden, especially with preventable and non-chronic GI diseases.